Miguel Melendez Munoz
General Practice · Kissimmee, FLNPI 1245216522
Payments from drug & device makers
Across 1,074 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Johnson & Johnson$2K
- plus $9K from 26 others
What the payments were for
- Food & beverage$24,640100%
- Education$1010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 195 | $4,317 |
| Alkermes, Inc. | 87 | $2,464 |
| Otsuka America Pharmaceutical, Inc. | 109 | $2,443 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 93 | $2,333 |
| Teva Pharmaceuticals USA, Inc. | 95 | $2,084 |
| Johnson & Johnson | 88 | $1,838 |
| Neurocrine Biosciences, Inc. | 55 | $1,286 |
| Vanda Pharmaceuticals Inc. | 48 | $1,177 |
| Axsome Therapeutics, Inc. | 32 | $1,142 |
| Sunovion Pharmaceuticals Inc. | 50 | $914 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $748 |
| Lundbeck LLC | 33 | $600 |
| E.r. Squibb & Sons, L.L.C. | 20 | $477 |
| Idorsia Pharmaceuticals US Inc | 24 | $435 |
| Ironshore Pharmaceuticals Inc. | 30 | $427 |
| Supernus Pharmaceuticals, Inc. | 6 | $326 |
| Boehringer Ingelheim | 2 | $271 |
| Livanova USA, Inc. | 3 | $265 |
| Almatica Pharma LLC | 10 | $201 |
| Tris Pharma Inc | 7 | $196 |
| Corium, LLC | 3 | $156 |
| Neuronetics, Inc. | 2 | $154 |
| Indivior Inc. | 5 | $109 |
| Eisai Inc. | 5 | $90 |
| Avanir Pharmaceuticals, Inc. | 5 | $83 |
| Collegium Pharmaceutical, Inc. | 3 | $50 |
| Merck | 2 | $38 |
| Noven Therapeutics, LLC | 2 | $33 |
| Shire North American Group Inc | 2 | $32 |
| Neos Therapeutics, LP | 2 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,804
- VRAYLAR$1,248
- ARISTADA$994
- CAPLYTA$959
- ABILIFY MAINTENA$490
- LATUDA$463
- Austedo XR$462
- Auvelity$372
- AUSTEDO$365
- QELBREE$251
- ARISTADA INITIO$249
- INGREZZA$244
- ABILIFY ASIMTUFII$243
- SPRAVATO$225
- INVEGA SUSTENNA$214
- INVEGA TRINZA$214
- COBENFY$126
- VIVITROL$125
- Fanapt$125
- Azstarys$122
How this compares
$24,742 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 165 | $231,181 |
| RexultiBrexpiprazole | 79 | $125,539 |
| CaplytaLumateperone Tosylate | 65 | $109,042 |
| AustedoDeutetrabenazine | 15 | $98,816 |
| LybalviOlanzapine/Samidorphan Malate | 48 | $71,443 |
| TrintellixVortioxetine Hydrobromide | 139 | $70,440 |
| Lurasidone Hcl | 160 | $60,392 |
| Invega SustennaPaliperidone Palmitate | 20 | $59,386 |
| QuviviqDaridorexant Hcl | 77 | $37,730 |
| AristadaAripiprazole Lauroxil | 15 | $33,459 |
| Aripiprazole | 259 | $31,918 |
| Duloxetine Hcl | 438 | $13,939 |
| Bupropion XlBupropion Hcl | 671 | $13,767 |
| Trazodone Hcl | 676 | $12,091 |
| BelsomraSuvorexant | 28 | $12,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $4,317 | $231,181165 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,443 | $125,53979 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,333 | $109,04265 claims |
| Alkermes, Inc.Lybalvi, Aristada | $2,464 | $104,90263 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $2,084 | $98,81615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $748 | $77,659158 claims |
| Johnson & JohnsonInvega Sustenna | $1,838 | $59,38620 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $435 | $37,73077 claims |
| MerckBelsomra | $38 | $12,05228 claims |
| Almatica Pharma LLCSertraline Hcl | $201 | $2,003386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Kissimmee
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.